Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Withdrawn 1Terminated 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Neoplasms 3216Carcinoma, Non-Small-Cell Lung 2729Breast Neoplasms 2551Colorectal Neoplasms 1463Prostatic Neoplasms 1307Neoplasm Metastasis 1301Multiple Myeloma 1112Melanoma 1103Ovarian Neoplasms 1006Lung Neoplasms 945Recurrence 924Leukemia, Myeloid, Acute 879Pancreatic Neoplasms 833Lymphoma, Non-Hodgkin 767Lymphoma 713Stomach Neoplasms 692Carcinoma, Renal Cell 660Carcinoma, Hepatocellular 647Leukemia, Lymphocytic, Chronic, B-Cell 560Squamous Cell Carcinoma of Head and Neck 550Lymphoma, Follicular 515Head and Neck Neoplasms 490Glioblastoma 473Small Cell Lung Carcinoma 447Lymphoma, Large B-Cell, Diffuse 440Triple Negative Breast Neoplasms 436Advanced Solid Tumors 432Leukemia 426Uterine Cervical Neoplasms 420Urinary Bladder Neoplasms 405

Interventions

XENP 1595 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Tauopathies × Clear all
NCT05522387 2026-02-27

An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease

Inmune Bio, Inc.

Phase 2 Terminated
11 enrolled
CNS

Alzheimer Disease, Mental Disorders, Brain Diseases, Central Nervous System Diseases, Dementia, Inflammation, Nervous System Diseases, Neurodegenerative Diseases, Neurocognitive Disorders, Tauopathies

NCT05321498 2023-09-28

Study to Assess the Efficacy of XPro1595 in Patients With Mild Cognitive Impairment With Biomarkers of Inflammation

Inmune Bio, Inc.

Phase 2 Withdrawn
CNS

Alzheimer Disease, Mental Disorders, Brain Diseases, Central Nervous System Diseases, Dementia, Inflammation, Nervous System Diseases, Neurodegenerative Diseases, Tauopathies, Cognitive Dysfunction

Data powered by HemOnc (CC BY 4.0) Colophon âš¡